A multidisciplinary Delphi consensus on budesonide aqueous nasal spray in managing upper respiratory diseases.

IF 2 Q3 RESPIRATORY SYSTEM
Giorgio Ciprandi, Ignazio La Mantia, Attilio Varricchio, Study Group On Topical Nasal Therapy
{"title":"A multidisciplinary Delphi consensus on budesonide aqueous nasal spray in managing upper respiratory diseases.","authors":"Giorgio Ciprandi, Ignazio La Mantia, Attilio Varricchio, Study Group On Topical Nasal Therapy","doi":"10.5826/mrm.2025.1015","DOIUrl":null,"url":null,"abstract":"<p><p>Allergic rhinitis (AR), non-allergic rhinitis (NAR), and chronic rhinosinusitis with nasal polyps (CRSwNP) share a type 2 inflammation. Thus, intranasal corticosteroids (INCS) are recommended for managing these diseases. In this regard, budesonide aqueous nasal spray (BANS) has been an effective and safe INCS available for decades. As a recent Delphi consensus and a survey explored the use of topical nasal therapy in practice, a panel of experts promoted a multidisciplinary Delphi consensus on BANS in daily practice. Forty-six Italian expert otorhinolaryngologists, allergologists, and pediatricians participated in the initiative. Twenty-one statements were voted on. There was a large agreement with all statements. Thus, this document proposed a valuable BANS use in managing patients with AR, NAR, or CRSwNP considering the relevant activity on dampening type 2 inflammation. Moreover, the safety profile was considered good, also concerning the bioavailability issue. However, based on the severity of the disease, BANS use should be prescribed as cycles or for prolonged periods.  In conclusion, the present multidisciplinary Delphi consensus supported BANS use in upper airway type 2 diseases.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"20 ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multidisciplinary Respiratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5826/mrm.2025.1015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Allergic rhinitis (AR), non-allergic rhinitis (NAR), and chronic rhinosinusitis with nasal polyps (CRSwNP) share a type 2 inflammation. Thus, intranasal corticosteroids (INCS) are recommended for managing these diseases. In this regard, budesonide aqueous nasal spray (BANS) has been an effective and safe INCS available for decades. As a recent Delphi consensus and a survey explored the use of topical nasal therapy in practice, a panel of experts promoted a multidisciplinary Delphi consensus on BANS in daily practice. Forty-six Italian expert otorhinolaryngologists, allergologists, and pediatricians participated in the initiative. Twenty-one statements were voted on. There was a large agreement with all statements. Thus, this document proposed a valuable BANS use in managing patients with AR, NAR, or CRSwNP considering the relevant activity on dampening type 2 inflammation. Moreover, the safety profile was considered good, also concerning the bioavailability issue. However, based on the severity of the disease, BANS use should be prescribed as cycles or for prolonged periods.  In conclusion, the present multidisciplinary Delphi consensus supported BANS use in upper airway type 2 diseases.

关于布地奈德鼻腔喷雾剂治疗上呼吸道疾病的多学科德尔菲共识。
过敏性鼻炎(AR)、非过敏性鼻炎(NAR)和伴有鼻息肉的慢性鼻炎(CRSwNP)都属于 2 型炎症。因此,建议使用鼻内皮质类固醇(INCS)来治疗这些疾病。在这方面,布地奈德水鼻喷雾剂(BANS)几十年来一直是一种有效、安全的 INCS。由于最近的德尔菲共识和一项调查探讨了鼻腔局部治疗在实践中的应用,一个专家小组推动了一项关于 BANS 在日常实践中的应用的多学科德尔菲共识。46 位意大利耳鼻喉科专家、过敏症专家和儿科医生参与了这项倡议。对 21 项声明进行了投票。所有声明都得到了广泛认同。因此,考虑到 BANS 在抑制 2 型炎症方面的相关活性,该文件建议将其用于管理 AR、NAR 或 CRSwNP 患者。此外,在生物利用度问题上,安全性也被认为是良好的。不过,根据疾病的严重程度,BANS 应按周期或长期使用。 总之,本次多学科德尔菲共识支持在上气道 2 型疾病中使用 BANS。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
23
审稿时长
>12 weeks
期刊介绍: Multidisciplinary Respiratory Medicine is the official journal of the Italian Respiratory Society - Società Italiana di Pneumologia (IRS/SIP). The journal publishes on all aspects of respiratory medicine and related fields, with a particular focus on interdisciplinary and translational research. The interdisciplinary nature of the journal provides a unique opportunity for researchers, clinicians and healthcare professionals across specialties to collaborate and exchange information. The journal provides a high visibility platform for the publication and dissemination of top quality original scientific articles, reviews and important position papers documenting clinical and experimental advances.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信